Related Experiment Videos
Immunotherapy with bispecific antibodies
1Laboratorium voor Fysiologie, Faculteit van de Geneeskunde en de Farmacie, Vrije Universiteit Brussel.
Verhandelingen - Koninklijke Academie Voor Geneeskunde Van Belgie
|January 1, 1995
Summary
Bispecific antibodies effectively target T cells to cancer cells, leading to tumor regression and long-term survival in animal models. Recombinant bispecific proteins produced in bacteria show similar efficacy, supporting their potential for cancer immunotherapy.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Monoclonal antibodies have limited anti-cancer effects.
- Bispecific antibodies can direct T cells to target cancer cells.
Purpose of the Study:
- To produce and evaluate bispecific antibodies for cancer immunotherapy.
- To assess the efficacy of hybrid-hybridoma and recombinant bispecific antibodies in targeting T cells to lymphoma cells.
Main Methods:
- Production of bispecific antibodies targeting murine B cell lymphomas and CD3 complex.
- In vitro characterization including flow cytometry, T cell proliferation, and IL-2 secretion assays.
- In vivo immunotherapy studies in tumor-bearing animals and production of recombinant bispecific proteins in E. coli.
Main Results:
- Bispecific antibodies successfully bridged T cells and lymphoma cells, inducing tumor regression and long-term survival.
- Recombinant bispecific proteins retained antigen specificity and in vitro/in vivo efficacy.
- Both hybrid-hybridoma and recombinant bispecific antibodies demonstrated significant anti-tumor activity.
Conclusions:
- Bispecific antibodies are effective in targeting T cells to tumors for cancer treatment.
- Recombinant protein production offers a streamlined approach for developing bispecific antibody therapies.
- These findings support the further investigation of bispecific antibodies for human cancer immunotherapy.